Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for United Therapeutics Corporation (UTHR : NSDQ)

• Company Description    United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Number of Employees: 1,400

• Price / Volume Information    Yesterday's Closing Price: $528.47 Daily Weekly Monthly 20 Day Moving Average: 404,784 shares Shares Outstanding: 42.45 (millions) Market Capitalization: $22,431.96 (millions) Beta: 0.58 52 Week High: $609.35 52 Week Low: $272.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.75% -3.46% 12 Week -7.51% -10.04% Year To Date 8.46% 0.42%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1000 SPRING ST - SILVER SPRING,MD 20910 USA ph: 301-608-9292 fax: 301-608-9291 ir@unither.com http://www.unither.com

• General Corporate Information    Officers Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James C. Edgemond - Chief Financial Officer and Treasurer Paul A. Mahon - Executive Vice President; General Counsel; and Cor Christopher Causey - Director Peer Information United Therapeutics Corporation (GSAC) United Therapeutics Corporation (CASIF) United Therapeutics Corporation (ALCD.) United Therapeutics Corporation (OMNN) United Therapeutics Corporation (CGPI.) United Therapeutics Corporation (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 91307C102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 42.45 Most Recent Split Date: 9.00 (2.00:1) Beta: 0.58 Market Capitalization: $22,431.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $7.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $26.63 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 11.22% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: 19.84 Trailing 12 Months: 19.51 PEG Ratio: 1.77 Price Ratios Price/Book: 3.80 Price/Cash Flow: 16.02 Price / Sales: 7.08 EPS Growth vs. Year Ago Period: -12.22% vs. Previous Quarter: -24.42% Sales Growth vs. Year Ago Period: -1.62% vs. Previous Quarter: -1.10% ROE 06/30/26 - - 03/31/26 - 19.24 12/31/25 - 19.30 ROA 06/30/26 - - 03/31/26 - 17.25 12/31/25 - 17.29 Current Ratio 06/30/26 - - 03/31/26 - 4.79 12/31/25 - 6.60 Quick Ratio 06/30/26 - - 03/31/26 - 4.50 12/31/25 - 6.28 Operating Margin 06/30/26 - - 03/31/26 - 40.62 12/31/25 - 41.94 Net Margin 06/30/26 - - 03/31/26 - 40.62 12/31/25 - 41.94 Pre-Tax Margin 06/30/26 - - 03/31/26 - 50.75 12/31/25 - 53.85 Book Value 06/30/26 - - 03/31/26 - 139.02 12/31/25 - 164.81 Inventory Turnover 06/30/26 - - 03/31/26 - 2.41 12/31/25 - 2.21 Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©